1. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
- Author
-
Anne E Holland, Yvonne Ng, Christine F McDonald, Hayley Barnes, Yet H. Khor, and Nicole S L Goh
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Vital capacity ,Placebo-controlled study ,Placebo ,law.invention ,03 medical and health sciences ,Idiopathic pulmonary fibrosis ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Diffusing capacity ,medicine ,Humans ,030212 general & internal medicine ,lcsh:RC705-779 ,business.industry ,Interstitial lung disease ,lcsh:Diseases of the respiratory system ,medicine.disease ,Prognosis ,Idiopathic Pulmonary Fibrosis ,030228 respiratory system ,business ,Cohort study - Abstract
In addition to facilitating healthcare delivery planning, reliable information about prognosis is essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This review aimed to evaluate the prognosis of patients with IPF without anti-fibrotic therapy. We included all cohort studies and the placebo arms of randomised controlled trials (RCTs) in IPF and follow-up of ≥12 months. Two reviewers independently evaluated studies for inclusion, assessed risk of bias and extracted data. A total of 154 cohort studies and 16 RCTs were included. The pooled proportions of mortality were 0.12 (95% CI 0.09–0.14) at 1–2 years, 0.38 (95% CI 0.34–0.42) between 2–5 years, and 0.69 (95% CI 0.59–0.78) at ≥5 years. The pooled mean overall survival was 4 years (95% CI 3.7–4.6) for studies with a follow-up duration of 10 years. At versuscohort study participants (0.14 (95% CI 0.12–0.17)). This review provides comprehensive information on the prognosis of IPF, which can inform treatment discussions with patients and comparisons for future studies with new therapies.
- Published
- 2020